See what we’re doing
Animal Life Sciences has licensed multiple drug technologies developed at the M.D. Anderson Cancer Center for the following diseases in animals:
1
Advanced chemotherapies for the treatment of leukemias and brain tumors
2
Cell signaling modulators and inhibitors of glycolysis for the treatment of a wide range of tumors
3
Topical treatments for a wide range of cancerous and noncancerous inflammatory skin conditions
OUR DRUG PIPELINE
Current Stages of Development and Testing
DRUG PORTFOLIO
10 Drugs in Development Across 5 Different Indications
Alongside direct investment of $60 million, over $43 million of grant funding (total of $103 million USD) has gone towards the development of our robust drug development pipeline.
brain cancer
- Targeting the treatment of spontaneous gliomas
- This technology was developed at Wake Forest University and licensed through a collaboration with WPD Pharmaceuticals. WPD101 has received a $10mm grant from the country of Poland
- Put brief detail on science
brain cancer
- Targeting the treatment of spontaneous gliomas
- This technology was developed at Wake Forest University and licensed through a collaboration with WPD Pharmaceuticals. WPD101 has received a $10mm grant from the country of Poland
- Put brief detail on science
brain cancer
- Targeting the treatment of spontaneous gliomas
- This technology was developed at Wake Forest University and licensed through a collaboration with WPD Pharmaceuticals. WPD101 has received a $10mm grant from the country of Poland
- Put brief detail on science
melanoma
- Targeting the treatment of spontaneous gliomas
- This technology was developed at Wake Forest University and licensed through a collaboration with WPD Pharmaceuticals. WPD101 has received a $10mm grant from the country of Poland
- Put brief detail on science
melanoma
- Targeting the treatment of spontaneous gliomas
- This technology was developed at Wake Forest University and licensed through a collaboration with WPD Pharmaceuticals. WPD101 has received a $10mm grant from the country of Poland
- Put brief detail on science
Leukemia
- Targeting the treatment of spontaneous gliomas
- This technology was developed at Wake Forest University and licensed through a collaboration with WPD Pharmaceuticals. WPD101 has received a $10mm grant from the country of Poland
- Put brief detail on science
Multiple Tumors
- Targeting the treatment of spontaneous gliomas
- This technology was developed at Wake Forest University and licensed through a collaboration with WPD Pharmaceuticals. WPD101 has received a $10mm grant from the country of Poland
- Put brief detail on science
Multiple Tumors
- Targeting the treatment of spontaneous gliomas
- This technology was developed at Wake Forest University and licensed through a collaboration with WPD Pharmaceuticals. WPD101 has received a $10mm grant from the country of Poland
- Put brief detail on science
Multiple Tumors
- Targeting the treatment of spontaneous gliomas
- This technology was developed at Wake Forest University and licensed through a collaboration with WPD Pharmaceuticals. WPD101 has received a $10mm grant from the country of Poland
- Put brief detail on science
Pancreatic Cancer
- Targeting the treatment of spontaneous gliomas
- This technology was developed at Wake Forest University and licensed through a collaboration with WPD Pharmaceuticals. WPD101 has received a $10mm grant from the country of Poland
- Put brief detail on science
- Targeting the treatment of spontaneous gliomas
- This technology was developed at Wake Forest University and licensed through a collaboration with WPD Pharmaceuticals. WPD101 has received a $10mm grant from the country of Poland
- Put brief detail on science